NEW HAVEN, Conn.--CuraGen recently announced a product discovery and pharmacogenomics agreement with COR Therapeutics. CuraGen said it will apply its SeqCalling, GeneCalling, and PathCalling technologies; related services; and pharmacogenomics expertise to identify new drug targets and develop new cardiovascular drugs.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.